Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07647042 · ClinicalTrials.gov registry record
A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 750
- Enrollment target
NCT07647042 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 750 participants.
The verdict
NCT07647042 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
The aim of this study was to describe treatment patterns, patient characteristics and clinical outcomes among hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) early breast cancer (eBC) patients who became eligible for treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in the real-world setting after the FDA approval of ribociclib treatment for eBC. The study used data abstracted from structured and unstructured patient electronic health records from sites available in the Integra Connect PrecisionQ database (secondary data use).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07647042
The ClinicalTrials.gov registry entry for NCT07647042 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07647042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07647042 about?
NCT07647042 is a clinical study titled "A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors". The aim of this study was to describe treatment patterns, patient characteristics and clinical outcomes among hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) early breast cancer (eBC) patients who became eligible for treatment with cyclin-dependent kinase 4 an...
What is the current status of trial NCT07647042?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2026-03-31. Estimated completion is 2026-04-30.
Who is sponsoring clinical trial NCT07647042?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.